Search results
Two Philadelphia-area biotech firms report progress on pursuit of a hepatitis B cure - Philadelphia...
The Business Journals· 17 hours agoTwo local life sciences companies reported progress this week on their efforts to develop a cure for...
Vir Biotechnology (VIR) Up on Positive Data From HDV Study
Zacks via Yahoo Finance· 16 hours agoVir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and...
GSK acquires Elsie to unlock oligonucleotide therapeutics
Pharmaceutical Technology via Yahoo Finance· 1 hour agoThe deal aligns with GSK's strategy of merging science and technology to expedite drug development...
Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 2
FierceBiotech· 2 days agoVir Biotechnology's hepatitis D combination therapy has shown early efficacy in results from a phase...
‘Unusual’ cancers emerged after the pandemic. Doctors ask if covid is to blame.
Washington Post· 1 day agoKashyap Patel looked forward to his team’s Friday lunches. It was 2021, a year into the coronavirus...
Transgenic murine model expresses BCP-mutated hepatitis B virus genome
Medical Xpress· 2 days agoChronic hepatitis B virus (HBV) infection can lead to advanced liver pathology. HBV has been infecting humans for over 10,000 years, with coordinated viral gene expression to establish persistent infection.
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 2 days agoAt the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable ...
We must remember the heroes of the AIDS epidemic, not just the trauma
LA Times via Yahoo News· 23 hours agoA hero’s journey often begins without knowing. For Jones, that first step was participating in a ...
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024...
Morningstar· 7 days agoTG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing ...
GSK, after 11-month romance, buys oligonucleotide partner Elsie for up to $50M
FierceBiotech· 20 hours agoAfter taking 11 months to get to know Elsie Biotechnologies' oligonucleotide platform, GSK is ready...
